Phase III Study of ASP1941 -A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 09 May 2019
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 31 Aug 2018 Biomarkers information updated
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2012 Planned End Date changed from 1 Jun 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.